CXCL8 and non-small cell lung carcinoma: Currently, multiple ongoing clinical trials in phase I/II are examining the safety and efficacy of HuMax-IL8 as a combination therapy in various cancer types, including prostate and pancreatic cancer, HCC, NSCLC, and other solid tumors (Table 3).